Diabetes mellitus and the risk of cancer

Minerva Endocrinologica

Volumn 36, Issue 3, 2011, Pages 187-209

  Pandey, A ^a   Forte, V ^a   Abdallah, M ^a   Alickaj, A ^a   Mahmud, S ^a   Asad, S ^a   McFarlane, S I ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

Diabetes mellitus; Insulin; Metformin; Neoplasms

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYTOKINE; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN GLARGINE; METFORMIN; SOMATOMEDIN C; SULFONYLUREA;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLON CANCER; CYTOKINE PRODUCTION; ENDOMETRIUM CANCER; EPIDEMIC; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LIVER CELL CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS CANCER; PREVALENCE; REVIEW; SIDE EFFECT; THYROID MEDULLARY CARCINOMA; UTERINE CERVIX CANCER;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULINS; METFORMIN; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84255168020     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Maynard GD. A statistical study in cancer death-rates. Biometrika 1910;7:276-304.
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
3. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-7. (Pubitemid 38747263)
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. 2011.
6. Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer 2003;98:894-9. (Pubitemid 37022087)
7. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA 2005;293:2479-86. (Pubitemid 40705729)
8. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298:2654-64. (Pubitemid 350254957)
9. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004;140:211-9.
10. Wild SH. Diabetes, treatments for diabetes and their effect on cancer incidence and mortality, attempts to disentangle the web of associations. Diabetologia 2011;54:1589-92.
11. Smith U, Gale EA. Cancer and diabetes: are we ready for prime time? Diabetologia 2010;53:1541-4.
12. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008;14:940-5. (Pubitemid 351753280)
13. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006;184:295-301. (Pubitemid 43049713)
14. Bhasker CR, Friedmann T. Insulin-like growth factor-1 coordinately induces the expression of fatty acid and cholesterol biosynthetic genes in murine C2C12 myoblasts. BMC Genomics 2008;9.535.
15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
16. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31.
17. Yang XL, Ma RC, Chan JC. Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer. Diabetologia 2011;54:709-10.
18. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78. (Pubitemid 351232031)
19. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006;55:1840-6. (Pubitemid 44324141)
20. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-81. (Pubitemid 38269336)
21. Baglietto L, English DR, Hopper JL, MacInnis RJ, Morris HA, Tilley WD et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009;115:171-9.
22. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-97. (Pubitemid 351880837)
23. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
24. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999;59:4516-8. (Pubitemid 29428949)
25. De MP. Insulin and its receptor: structure, function and evolution. Bioessays 2004;26:1351-62.
26. Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004;14:261-9. (Pubitemid 38878051)
27. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132:2208-25. (Pubitemid 46693749)
28. Jalving M, Gietema JA, Lefrandt JD, de JS, Reyners AK, Gans RO et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2309-80.
29. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
30. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res 2006;55:233-44.
31. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
32. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
33. Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 2007;27:3569-77. (Pubitemid 46726168)
34. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46.
35. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007;106:39-47. (Pubitemid 47498088)
36. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal 2009;7:14.
37. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001,86:972-9. (Pubitemid 32322967)
38. Salzman A, Wan CF, Rubin CS. Biogenesis, transit, and functional properties of the insulin proreceptor and modified insulin receptors in 3T3-L1 adipocytes. Use of monensin to probe proreceptor cleavage and generate altered receptor subunits. Biochemistry 1984;23.6555-65.
39. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7. (Pubitemid 46142798)
40. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96. (Pubitemid 43278292)
41. Dupont J, Leroith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res 2001;55 Suppl 2:22-6.
42. Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML et al. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol 2001;12:429-35. (Pubitemid 34274396)
43. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
44. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 1997;109):565-71.
45. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004,64:8620-9. (Pubitemid 39552075)
46. Leroith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37.
47. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131(11 Suppl):3109S-3120S. (Pubitemid 33070788)
48. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-9.
49. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91. (Pubitemid 39025053)
50. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007;99:1793-800. (Pubitemid 351767208)
51. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53. (Pubitemid 38529873)
52. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-36. (Pubitemid 44397568)
53. Chantelau E, Mayer D. Meeting report: 3rd international workshop on insulin & cancer heidelberg, Germany, October 30-31, 2010. Diabetol Metab Syndr 2010;2:73.
54. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A 1976;73:4536-40. (Pubitemid 8013935)
55. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79(8 Suppl):1527-34.
56. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
57. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000;275.9047-54.
58. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun 2008;377:136-40.
59. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006;66:10100-11. (Pubitemid 44672064)
60. Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling, implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 2008;111:79-91. (Pubitemid 352009232)
61. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 1972;32:226-32.
62. Rensing KL, Houttuijn Bloemendaal FM, Weijers EM, Richel DJ, Buller HR, Koolwijk P et al. Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? Diabetologia 2010;53.966-70.
63. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom WS, Okano H et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005;307:1976-8. (Pubitemid 40404709)
64. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12. (Pubitemid 46206663)
65. Liao S, Li J, Wang L, Zhang Y, Wang C, Hu M et al. Type 2 diabetes mellitus and characteristics of breast cancer in China. Asian Pac J Cancer Prev 2010;11:933-7.
66. Fontana SA, Baumann LC, Helberg C, Love RR. The delivery of preventive services in primary care practices according to chronic disease status. Am J Public Health 1997;87:1190-6.
67. McBean AM, Yu X. The underuse of screening services among elderly women with diabetes. Diabetes Care 2007;30:1466-72. (Pubitemid 46871156)
68. Lipscombe LL, Hux JE, Booth GL. Reduced screening mammography among women with diabetes. Arch Intern Med 2005;165:2090-5. (Pubitemid 41434583)
69. Zhao G, Ford ES, Ahluwalia IB, Li C, Mokdad AH. Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med 2009;24:270-5.
70. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-64.
71. Sassi F, Luft HS, Guadagnoli E. Reducing racial/ethnic disparities in female breast cancer: screening rates and stage at diagnosis. Am J Public Health 2006;96:2165-72. (Pubitemid 44865108)
72. Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat 2009;113:567-76.
73. Call R, Grimsley M, Cadwallader L, Cialone L, Hill M, Hreish V et al. Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med 2010;122:158-65.
74. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010;70:741-51.
75. Plymate SR, Hoop RC, Jones RE, Matej LA. Regulation of sex hormone-binding globulin production by growth factors. Metabolism 1990;39:967-70. (Pubitemid 20293945)
76. Singh A, Hamilton-Fairley D, Koistinen R, Seppala M, James VH, Franks S et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J Endocrinol 1990;124:R1-R3. (Pubitemid 20046146)
77. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Endocr Rev 1990;11:80-91. (Pubitemid 20101338)
78. Williams GP. The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. Eur J Cancer Prev 2010;19:256-71.
79. Li CI, Daling JR, Tang MT, Malone KE. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 2011;125:545-51.
80. Bartella V, Cascio S, Fiorio E, Auriemma A, Russo A, Surmacz E. Insulin-dependent leptin expression in breast cancer cells. Cancer Res 2008;68:4919-27.
81. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-7. (Pubitemid 46354334)
82. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003;26:1752-8. (Pubitemid 36929115)
83. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005;6:103-11. (Pubitemid 40197704)
84. Guastamacchia E, Resta F, Triggiani V, Liso A, Licchelli B, Ghiyasaldin S et al. Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:59-66. (Pubitemid 38854882)
85. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol 2009;27:2170-6.
86. Rollison DE, Giuliano AR, Sellers TA, Laronga C, Sweeney C, Risendal B et al. Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states. Am J Epidemiol 2008;167:447-56. (Pubitemid 351264144)
87. Stephansson O, Granath F, Ekbom A, Michels KB. Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study. Breast Cancer Res 2010;12:R14.
88. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981-7. (Pubitemid 351451984)
89. Huxley R, Ansary-Moghaddam A, Berrington de GA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83. (Pubitemid 40897433)
90. Chari ST, Leibson CL, Rabe KG, Ransom J, de AM, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-11. (Pubitemid 41096638)
91. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 2006;15:1458-63. (Pubitemid 44299315)
92. Pezzilli R, Casadei R, Morselli-Labate AM. Is type 2 diabetes a risk factor for pancreatic cancer? JOP 2009;10:705-6.
93. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-5. (Pubitemid 26054071)
94. Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E et al. Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med 2007;5:25.
95. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283:2552-8. (Pubitemid 30324198)
96. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-8.
97. Caudle AS, Kim HJ, Tepper JE, O'Neil BH, Lange LA, Goldberg RM et al. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer. Ann Surg Oncol 2008;15:1931-6.
98. Wu Y, Yakar S, Zhao L, Hennighausen L, Leroith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:1030-5. (Pubitemid 34160283)
99. Komninou D, Ayonote A, Richie JP, Jr., Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003;228:396-405. (Pubitemid 37203647)
100. Hoeflich A, Yang Y, Huber S, Rascher W, Koepf G, Blum WF et al. Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells. Am J Physiol 1996;271(5 Pt 1):E922-E931.
101. Schulz JH. The Economics of Aging. New York: Auburn House; 1992. p. 2011.
102. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4. (Pubitemid 28493768)
103. Limburg PJ, Anderson KE, Johnson TW, Jacobs DR, Jr., Lazovich D, Hong CP et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2005;14:133-7. (Pubitemid 40165293)
104. Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 1997;89:660-1. (Pubitemid 27200500)
105. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202. (Pubitemid 40095870)
106. La VC, Negri E, Decarli A, Franceschi S. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1997;6:1007-10. (Pubitemid 28007409)
107. Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 2005;28:1805-7. (Pubitemid 40923101)
108. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998;147:816-25. (Pubitemid 28244386)
109. Giouleme O, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011;17:444-8.
110. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 2008;53:2486-94.
111. Noh GY, Hwang DY, Choi YH, Lee YY. Effect of diabetes mellitus on outcomes of colorectal cancer. J Korean Soc Coloproctol 2010;26:424-8.
112. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009;169:937-45.
113. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004;47:1071-8. (Pubitemid 38918167)
114. Jackson FL, Hutson JC. Altered responses to androgen in diabetic male rats. Diabetes 1984;33:819-24. (Pubitemid 14038699)
115. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004;159:978-82. (Pubitemid 38608275)
116. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132:895-901. (Pubitemid 20363668)
117. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15.2056-62.
118. Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47-51. (Pubitemid 27023000)
119. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44.
120. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-54.
121. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-65.
122. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
123. Suissa S, Azoulay L, Dell'aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011 [Epub ahead of print].
124. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
125. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6. (Pubitemid 41780780)
126. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8.909-15.
127. Ben S, I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86.
128. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110:246-50.
129. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73. (Pubitemid 44799743)
130. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5. (Pubitemid 40813563)
131. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODI-AC-16. Diabetes Care 2010;33:322-6.
132. A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer [registered clinical trial], 2009. Clinical trial reg. no. NCT01101438, clinicaltrials.gov. Accessed 11 July 2011.
133. Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 2010;21:187-9.
134. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.
135. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008;31:1455-60.
136. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7. (Pubitemid 32472935)
137. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007;5:17.
138. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007;16:485-92. (Pubitemid 46824269)
139. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25:1476-81. (Pubitemid 46733074)
140. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7.
141. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like Peptide-1-based therapies. Gastroenterology 2011;141:150-6.
142. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat 2011 [Epub ahead of print].